Open AccessA comparison of EGFR mutation status in tissue and plasma cell-free DNA detected by ADx-ARMS in advanced lung adenocarcinoma patients
Author(s) -
Hong Xu,
Adam Abdul Hakeem Baidoo,
Shanshan Su,
Junru Ye,
Chengshui Chen,
Yupeng Xie,
Luca Bertolaccini,
Mahmoud Ismail,
Biagio Ricciuti,
Calvin S.H. Ng,
Raja M. Flores,
Yuping Li
Publication year - 2019
Publication title -
translational lung cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 41
eISSN - 2226-4477
pISSN - 2218-6751
DOI - 10.21037/tlcr.2019.03.10
Subject(s) - medicine , gefitinib , adenocarcinoma , epidermal growth factor receptor , lung cancer , oncology , mutation , cancer research , lung , cell free fetal dna , tyrosine kinase inhibitor , prospective cohort study , gene mutation , cancer , pathology , gene , biology , genetics , pregnancy , fetus , prenatal diagnosis
Previous studies have shown that there are different methods used to detect the epidermal growth factor receptor ( EGFR ) mutation status in plasma cell-free DNA (cfDNA) for advanced lung adenocarcinoma patients including the ADx-Amplification Refractory Mutation System (ADx-ARMS). We explored the performance of the ADx-ARMS in detecting the EGFR mutations in cfDNA.